



WORLDWIDE PHARMA SOLUTION

PHARMACEUTICAL EXPERTISE | EUROPEAN FOCUS

COMPANY PROFILE & API PORTFOLIO

Connecting Expertise Expanding Possibilities

Pharmaceutical solutions through trusted API supply, industry expertise and strategic commercial development across European markets.

WWPS - WORLDWIDE PHARMA SOLUTIONS, UNIPessoal LDA
PORTUGAL | 2026

COMPANY AT A GLANCE

A practical partner for pharmaceutical growth

WWPS is a Portugal-based pharmaceutical solutions company connecting manufacturers, pharmaceutical businesses and commercial opportunities across Portugal, Spain and selected European markets.

LISTED APIs	PORTFOLIO GROUPS	SUPPLY NETWORK	MARKET FOCUS
181	19	GLOBAL	EU

OUR ROLE

We support customers from initial product identification through technical and regulatory documentation coordination, commercial alignment and ongoing supply communication.

OUR DIFFERENCE

Local market understanding, direct manufacturer relationships and project-by-project attention create a focused route from opportunity to a workable pharmaceutical partnership.

Built for enduring pharmaceutical partnerships

Our objective is simple: to build reliable pharmaceutical partnerships that create sustainable value for customers and manufacturing partners.

The portfolio also includes a separate intermediates and synthesis reference catalogue. Q4 additions are subject to technical and regulatory confirmation.

WHAT WE DO

Pharmaceutical solutions built around your business

Every project has different technical, regulatory and commercial requirements. WWPS structures its support around the needs of the customer, intended market and product.

01 API Supply & Sourcing

Access to a broad API portfolio through selected manufacturing partners, with product options evaluated against technical, documentation and commercial requirements.

02 Commercial & Market Development

Identification and development of sustainable opportunities, with particular focus on Portugal, Spain and selected European markets.

03 Commercial Representation

Focused, relationship-led market representation for selected pharmaceutical manufacturers and industry partners.

04 Regulatory & Documentation Coordination

Communication and coordination around the documentation needed for qualification and commercial evaluation.

05 Supply & International Coordination

Practical coordination between manufacturing partners and customers throughout evaluation and commercial supply.

06 Consulting & Project Support

Selected support for market assessment, supplier and product evaluation, commercial strategy and partnership development.

SELECTED EXPERIENCE

Experience across products and pharmaceutical projects

WWPS works with API manufacturers in China and India, finished-product manufacturers across the Middle East, and pharmaceutical companies seeking reliable technical and commercial partnerships. Our activities extend from product and supplier identification to documentation coordination, commercial development and selected pharmaceutical project consulting.

PROJECT REFERENCE / IRAQ

Oncology manufacturing project

Advisory and coordination support for the planning and development of a specialized oncology manufacturing line in Iraq.

SUPPORT AREAS

Project scoping and partner identification
Technical, documentation and commercial alignment

PARTNERSHIP SUPPORT

01

API sourcing & supply

Manufacturer and product identification, documentation follow-up and coordination of samples and commercial requirements.

02

Finished-product partnerships

Collaboration with manufacturers across the Middle East to evaluate product fit, commercial opportunities and partnership requirements.

03

Ongoing partnership management

Continued communication, issue follow-up and supply coordination as the customer-manufacturer relationship develops.

INTERNATIONAL NETWORK

Pharmaceutical partnerships across regions



BASED IN PORTUGAL, WORKING ACROSS REGIONS

A network shaped around each partnership

WWPS coordinates manufacturing relationships, commercial opportunities and selected pharmaceutical projects across Europe, the Middle East and Asia. Communication and follow-through continue as each partnership develops.

EUROPE

Commercial development

Market engagement and opportunity development from Portugal.

CHINA & INDIA

API relationships

Manufacturer engagement, product identification and documentation coordination.

MIDDLE EAST


Products & projects

Finished-product partnerships and selected pharmaceutical project support.

COMMERCIAL REACH

European market focus

Our commercial work is concentrated where local understanding, direct communication and disciplined project coordination can create the greatest value.



Local insight

Direct market engagement from Portugal, with active attention to customer priorities and commercial context

Targeted development

Focused opportunity development in Portugal, Spain and selected European markets

Coordinated execution

Each opportunity is evaluated against product fit, regulatory scope, destination territory, documentation readiness and commercial feasibility

PRODUCT & DOCUMENTATION

Regulatory portfolio

The API portfolio includes 181 entries. Existing documentation indications are retained. A dash in the product tables indicates information not supplied or not verified.

CEP	EU-DMF	US-DMF	CEP IN PROGRESS
15	17	27	7

Selected priority molecules

API	CAS No.	Documentation
Dexamethasone Sodium Phosphate	2392-39-4	CEP, EU-DMF, US-DMF
Prednisolone	50-24-8	CEP, EU-DMF, US-DMF
Methylprednisolone	83-43-2	CEP, EU-DMF, US-DMF
Hydrocortisone	50-23-7	CEP, EU-DMF, US-DMF
Mometasone Furoate	83919-23-7	CEP in progress
Ethinyl Estradiol	57-63-6	CEP, EU-DMF, US-DMF
Progesterone	57-83-0	CEP, EU-DMF, US-DMF
Megestrol Acetate	595-33-5	CEP, EU-DMF, US-DMF
Cyproterone Acetate	427-51-0	CEP, EU-DMF
Dydrogesterone	152-62-5	CEP in progress, EU-DMF
Rocuronium Bromide	119302-91-9	CEP, EU-DMF, US-DMF
Eplerenone	107724-20-9	CEP, EU-DMF

Regulatory and quality note

WWPS does not issue regulatory approvals or certificates. Final status, validity, manufacturing-site coverage, GMP status, intended dosage form and destination-market suitability must be verified during qualification. A Commercial production stage is not a regulatory approval.

COMPLETE API PORTFOLIO / Q4 2026

181 active pharmaceutical ingredients

The complete WWPS portfolio with CAS numbers and indicated documentation status. Includes 62 additions to the previous 119-entry portfolio.

A dash indicates information not supplied or not verified. Production stage does not establish regulatory approval. Manufacturing-site GMP coverage requires product-specific confirmation.

01 Corticosteroids & Anti-inflammatory Systemic, injectable & ophthalmic

API	CAS No.	Application / scope	Documentation
Dexamethasone	50-02-2	High-volume corticosteroid; anti-inflammatory / oncology support	US-DMF
Dexamethasone Sodium Phosphate	2392-39-4	Injectable anti-inflammatory & immunosuppressant corticosteroid	CEP, EU-DMF, US-DMF
Hydrocortisone	50-23-7	Adrenal insufficiency; systemic & topical corticosteroid	CEP, EU-DMF, US-DMF
Methylprednisolone	83-43-2	Injectable / oral corticosteroid; hospital anti-inflammatory	CEP, EU-DMF, US-DMF
Prednisolone	50-24-8	Oral / ophthalmic corticosteroid; broad anti-inflammatory use	CEP, EU-DMF, US-DMF
Prednisone	53-03-2	Oral corticosteroid & immunosuppressant	CEP, EU-DMF, US-DMF
Prednisone Acetate	125-10-0	Corticosteroid ester; oral anti-inflammatory	CEP, EU-DMF, US-DMF

02 Dermatology Topical corticosteroids & anti-androgens

API	CAS No.	Application / scope	Documentation
Betamethasone Valerate	2152-44-5	Topical corticosteroid	US-DMF
Clascoterone	19608-29-8	Topical anti-androgen for acne (novel, high-value)	US-DMF
Hydrocortisone Butyrate	13609-67-1	Topical corticosteroid ester	CEP in progress
Mometasone Furoate	83919-23-7	Topical / nasal corticosteroid	CEP in progress
Mometasone Furoate Monohydrate	141646-00-6	Aqueous nasal-spray corticosteroid form	CEP in progress

03 Respiratory & ENT Inhaled & nasal therapies

API	CAS No.	Application / scope	Documentation
Tiotropium Bromide	136310-93-5	Long-acting anticholinergic bronchodilator (COPD)	US-DMF

04 Sex Hormones — Estrogens

HRT & contraceptive estrogens

API	CAS No.	Application / scope	Documentation
Estradiol Hemihydrate	35380-71-3	Core HRT estrogen (menopause)	CEP, EU-DMF, US-DMF
Estradiol Valerate	979-32-8	HRT & injectable estrogen ester	CEP, EU-DMF
Ethinyl Estradiol	57-63-6	Oral-contraceptive estrogen backbone	CEP, EU-DMF, US-DMF

05 Sex Hormones — Progestogens

Contraceptive & HRT progestins

API	CAS No.	Application / scope	Documentation
Cyproterone Acetate	427-51-0	Anti-androgen; acne, prostate, contraception	CEP, EU-DMF
Dydrogesterone	152-62-5	Oral progestogen (luteal support); high-value	CEP in progress, EU-DMF
Levonorgestrel	797-63-7	Contraceptive & emergency contraception progestin	CEP in progress, US-DMF
Medroxyprogesterone Acetate	71-58-9	Depot contraceptive; oncology	CEP in progress, US-DMF
Megestrol Acetate	595-33-5	Appetite stimulant; oncology cachexia	CEP, EU-DMF, US-DMF
Mifepristone	84371-65-3	Progesterone-receptor modulator	CEP in progress, EU-DMF, US-DMF
Norethisterone	68-22-4	Contraceptive & HRT progestin	CEP, EU-DMF
Progesterone	57-83-0	Luteal support & HRT; largest-volume hormone	CEP, EU-DMF, US-DMF

06 Androgens / TRT

Testosterone & esters

API	CAS No.	Application / scope	Documentation
Testosterone	58-22-0	Testosterone-replacement therapy (TRT)	US-DMF
Testosterone Cypionate	58-20-8	Injectable TRT ester	US-DMF
Testosterone Decanoate	5721-91-5	Component of mixed-ester TRT	US-DMF
Testosterone Enanthate	315-37-7	Core injectable TRT ester	US-DMF
Testosterone Propionate	57-85-2	Short-acting TRT ester	US-DMF
Testosterone Tridecanoate	488836-58-4	Long-acting TRT ester	US-DMF
Testosterone Undecanoate	5949-44-0	Long-acting TRT ester	US-DMF

07 Muscle Relaxants

Neuromuscular blockers & reversal

API	CAS No.	Application / scope	Documentation
Rocuronium Bromide	119302-91-9	Non-depolarising neuromuscular blocker (anaesthesia)	CEP, EU-DMF, US-DMF
Vecuronium Bromide	50700-72-6	Non-depolarising neuromuscular blocker	US-DMF

08 Cardiovascular & Coagulation

Statins, anticoagulants, antihypertensives

API	CAS No.	Application / scope	Documentation
Apixaban	503612-47-3	Direct factor-Xa anticoagulant	-
Atorvastatin Calcium	134523-03-8	Statin; hypercholesterolaemia	-
Eplerenone	107724-20-9	Mineralocorticoid antagonist (heart failure, hypertension)	CEP, EU-DMF
Rivaroxaban	366789-02-8	Direct factor-Xa anticoagulant	-
Rosuvastatin Calcium	147098-20-2	Statin; hypercholesterolaemia	-

09 Diabetes & Metabolic

DPP-4 & SGLT2 inhibitors

API	CAS No.	Application / scope	Documentation
Alogliptin Benzoate	850649-62-6	DPP-4 inhibitor (type-2 diabetes)	-
Canagliflozin Monohydrate	1809403-05-1	SGLT2 inhibitor (type-2 diabetes)	-
Dapagliflozin Propanediol	960404-48-2	SGLT2 inhibitor (type-2 diabetes, HF, CKD)	-
Empagliflozin	864070-44-0	SGLT2 inhibitor (type-2 diabetes, HF)	-
Linagliptin	668270-12-0	DPP-4 inhibitor (type-2 diabetes)	-
Sitagliptin Phosphate Monohydrate	654671-77-9	DPP-4 inhibitor (type-2 diabetes)	-

10 Central Nervous System

Antidepressants & neurology

API	CAS No.	Application / scope	Documentation
Brexanolone	516-54-1	Postpartum-depression neuroactive steroid	US-DMF
Duloxetine Hydrochloride	136434-34-9	SNRI antidepressant / neuropathic pain	-
Escitalopram Oxalate	219861-08-2	SSRI antidepressant	-
Fingolimod Hydrochloride	162359-56-0	Multiple-sclerosis immunomodulator	-

11 Gastrointestinal

PPIs & acid blockers

API	CAS No.	Application / scope	Documentation
Esomeprazole Magnesium Dihydrate	217087-10-0	Proton-pump inhibitor (GERD)	-
Vonoprazan Fumarate	1260141-27-2	Potassium-competitive acid blocker	-

12 Anti-infective

Antibacterial, antifungal, antimalarial

API	CAS No.	Application / scope	Documentation
Isavuconazonium Sulfate	946075-13-4	Broad-spectrum systemic antifungal	-
Mefloquine Hydrochloride	51773-92-3	Antimalarial	-
Moxifloxacin Hydrochloride	186826-86-8	Fourth-generation fluoroquinolone antibacterial	-

13 Oncology & Haematology

Targeted kinase & pathway inhibitors

API	CAS No.	Application / scope	Documentation
Abemaciclib	1231929-97-7	CDK4/6 inhibitor (breast cancer)	-
Alectinib Hydrochloride	1256589-74-8	ALK inhibitor (NSCLC)	-
Axitinib	319460-85-0	VEGFR tyrosine-kinase inhibitor (RCC)	-
Darolutamide	1297538-32-9	Androgen-receptor inhibitor (prostate cancer)	-
Eltrombopag Olamine	496775-62-3	Thrombopoietin-receptor agonist	-
Lenvatinib Mesilate	857890-39-2	Multi-kinase inhibitor (thyroid, HCC)	-
Niraparib Tosylate	1038915-73-9	PARP inhibitor (ovarian cancer)	-
Palbociclib	571190-30-2	CDK4/6 inhibitor (breast cancer)	-
Regorafenib	755037-03-7	Multi-kinase inhibitor (colorectal cancer)	-
Relugolix	737789-87-6	GnRH-receptor antagonist (prostate cancer)	-
Ribociclib Succinate	1374639-75-4	CDK4/6 inhibitor (breast cancer)	-
Sorafenib Tosylate	475207-59-1	Multi-kinase inhibitor (HCC, RCC)	-
Venetoclax	1257044-40-8	BCL-2 inhibitor (haematological malignancy)	-

14 Immunology & Inflammation

JAK inhibitors & immunomodulators

API	CAS No.	Application / scope	Documentation
Baricitinib	1187594-09-7	JAK inhibitor (rheumatoid arthritis)	-
Ruxolitinib Phosphate	1092939-17-7	JAK1/2 inhibitor (myelofibrosis)	-
Tofacitinib Citrate	540737-29-9	JAK inhibitor (rheumatoid arthritis)	-
Upadacitinib	1310726-60-3	JAK inhibitor (rheumatoid arthritis, IBD)	-

15 Specialty & Rare Disease

CFTR modulators, CGRP, urology

API	CAS No.	Application / scope	Documentation
Elexacaftor	2216712-66-0	CFTR corrector (cystic fibrosis)	-
Ivacaftor	873054-44-5	CFTR potentiator (cystic fibrosis)	-
Lumacaftor	936727-05-8	CFTR corrector (cystic fibrosis)	-

15 Specialty & Rare Disease

CFTR modulators, CGRP, urology

API	CAS No.	Application / scope	Documentation
Rimegepant Sulfate	1374024-48-2	CGRP-receptor antagonist (migraine)	-
Solifenacin	242478-37-1	Muscarinic antagonist (overactive bladder)	-
Tadalafil	171596-29-5	PDE5 inhibitor (ED, BPH, PAH)	-
Tezacaftor	1152311-62-0	CFTR corrector (cystic fibrosis)	-

16 Peptide Therapeutics

GLP-1 & specialty peptides

API	CAS No.	Application / scope	Documentation
Abaloparatide Acetate	247062-33-5	PTHrP analogue (osteoporosis)	-
Atosiban Acetate	90779-69-4	Oxytocin antagonist (preterm labour)	-
Bivalirudin	128270-60-0	Direct thrombin inhibitor (anticoagulant)	-
Carbetocin Acetate	37025-55-1	Oxytocin analogue (postpartum haemorrhage)	-
Eptifibatide	188627-80-7	GP IIb/IIIa antagonist (antiplatelet)	-
Etelcalcetide	1262780-97-1	Calcimimetic (secondary hyperparathyroidism)	-
Exenatide	141732-76-5	GLP-1 agonist (type-2 diabetes)	-
Ganirelix Acetate	123246-29-7	GnRH antagonist (assisted reproduction)	-
Icatibant Acetate	138614-30-9	Bradykinin B2 antagonist (angioedema)	-
Lanreotide	108736-35-2	Somatostatin analogue (acromegaly, NET)	-
Linaclotide	851199-59-2	GC-C agonist (IBS-C, chronic constipation)	-
Liraglutide	204656-20-2	GLP-1 agonist (diabetes, weight management)	-
Octreotide Acetate	83150-76-9	Somatostatin analogue (acromegaly, NET)	-
Semaglutide	910463-68-2	GLP-1 agonist (type-2 diabetes, weight management)	-
Teriparatide Acetate	52232-67-4	PTH analogue (osteoporosis)	-
Terlipressin Acetate	14636-12-5	Vasopressin analogue (hepatorenal syndrome)	-
Thymosin Alpha-1	62304-98-7	Immunomodulator	-
Tirzepatide	2023788-19-2	GIP/GLP-1 co-agonist (diabetes, weight management)	-
Ziconotide Acetate	107452-89-1	N-type calcium-channel blocker (chronic pain)	-

17 Amino Acids

Ph.Eur./USP pharmaceutical grade

API	CAS No.	Application / scope	Documentation
Glycine	56-40-6	-	-
L-Alanine	56-41-7	-	-
L-Aspartic Acid	56-84-8	-	-

17 Amino Acids

Ph.Eur./USP pharmaceutical grade

API	CAS No.	Application / scope	Documentation
L-Glutamic Acid	56-86-0	-	-
L-Isoleucine	73-32-5	-	-
L-Leucine	61-90-5	-	-
L-Lysine Acetate	57282-49-2	-	-
L-Lysine Hydrochloride	657-27-2	-	-
L-Methionine	63-68-3	-	-
L-Phenylalanine	63-91-2	-	-
L-Serine	56-45-1	-	-
L-Threonine	72-19-5	-	-
L-Tryptophan	73-22-3	-	-
L-Tyrosine	60-18-4	-	-

18 Cosmetic & Nutraceutical Actives

Anti-ageing & regenerative actives

API	CAS No.	Application / scope	Documentation
Acetyl Hexapeptide-8 (Argireline)	616204-22-9	Expression-line peptide	-
GHK-Cu (Tripeptide-1 Copper)	89030-95-5	Anti-ageing skin-conditioning peptide	-
L-(+)-Ergothioneine	497-30-3	Antioxidant anti-ageing active	-
Nicotinamide Riboside Chloride (NRC)	23111-00-4	NAD+ precursor	-
Nonapeptide-1	158563-45-2	Skin-brightening peptide	-
Palmitoyl Tripeptide-5	623172-56-5	Anti-ageing peptide	-
Polydeoxyribonucleotide (PDRN)	100403-24-5	Tissue-regeneration activator	-
β -Nicotinamide Adenine Dinucleotide (NAD)	53-84-9	Cellular-energy anti-ageing active	-
β -Nicotinamide Mononucleotide (NMN)	1094-61-7	NAD+ precursor / anti-ageing	-

19 Expanded API Portfolio

Q4 2026 additions. Regulatory documentation and manufacturing-site GMP status require confirmation.

API	CAS No.	Application / scope	Documentation
Abrocitinib	1622902-68-4	-	-
Acoramidis	1446711-81-4	-	-
Aticaprant	1174130-61-0	-	-
Avatrombopag Maleate	677007-74-8	-	-
Bardoxolone	218600-44-3	-	-

19 Expanded API Portfolio

Q4 2026 additions. Regulatory documentation and manufacturing-site GMP status require confirmation.

API	CAS No.	Application / scope	Documentation
Baxdrostat	1428652-17-8	-	-
Brensocatib	1802148-05-5	-	-
Brexiprazole	913611-97-9	-	-
Camizestrant	2222844-89-3	-	-
Crisaborole	906673-24-3	-	-
Danicopan	1903768-17-1	-	-
Daraxonrasib	2765081-21-6	-	-
Elacestrant	722533-56-4	-	-
Elagolix Sodium	832720-36-2	-	-
Elinzanetant	929046-33-3	-	-
Elobixibat	1633824-78-8	-	-
Eltrombopag	496775-61-2	-	-
Enzalutamide	915087-33-1	-	-
Fezolinetant	1629229-37-3	-	-
Fingolimod	162359-55-9	-	-
Gepotidacin	1075236-89-3	-	-
Givinostat	497833-27-9	-	-
Iptacopan Hydrochloride	2447007-60-3	-	-
Ivabradine Hydrochloride	148849-67-6	-	-
KT-474	2432994-31-3	-	-
Lesinurad	878672-00-5	-	-
Letermovir	917389-32-3	-	-
Linzagolix Choline	935283-04-8	-	-
Lumateperone Tosylate	1187020-80-9	-	-
Milvexian	1802425-99-5	-	-
Muvalaplin	2565656-70-2	-	-
Nemorexant (daridorexant hydrochloride)	1505484-82-1	-	-
Nintedanib	656247-17-5	-	-
Nintedanib Ethanesulfonate	656247-18-6	-	-
Omaveloxolone	1474034-05-3	-	-
Orforglipron	3008544-96-2	-	-
Ozanimod	1306760-87-1	-	-
Pacritinib	937272-79-2	-	-
Peficitinib Hydrobromide	1353219-05-2	-	-
Pemafibrate	848259-27-8	-	-
Pirfenidone	53179-13-8	-	-

19 Expanded API Portfolio

Q4 2026 additions. Regulatory documentation and manufacturing-site GMP status require confirmation.

API	CAS No.	Application / scope	Documentation
Ponesimod	854107-55-4	-	-
Remibrutinib	1787294-07-8	-	-
Rimegepant	1289023-67-1	-	-
Risdipram	1825352-65-5	-	-
Roflumilast	162401-32-3	-	-
Seladelpar	928821-40-3	-	-
Selexipag	475086-01-2	-	-
Seltorexant	1293281-49-8	-	-
Siponimod	1230487-00-9	-	-
Sparsentan	254740-64-2	-	-
Suzetrigine	2649467-58-1	-	-
Tafamidis	594839-88-0	-	-
Tasimelteon	609799-22-6	-	-
Tenapanor	1234423-95-0	-	-
Tenapanor Hydrochloride	1234365-97-9	-	-
Vanzacaftor	2374124-49-7	-	-
Vericiguat	1350653-20-1	-	-
Vibegron	1190389-15-1	-	-
Vonoprazan	881681-00-1	-	-
Xanomeline	131986-45-3	-	-
Zavegepant	1337918-83-8	-	-

Availability, documentation, manufacturing-site coverage and destination-market suitability must be confirmed for each enquiry. Supply is subject to applicable intellectual property rights and regulatory requirements.

INTERMEDIATES & SYNTHESIS REFERENCES

A separate portfolio for synthesis projects

Search the online intermediates catalogue by target API, CAS number or production stage. Finished APIs and intermediates are presented separately to support product selection.

CATALOGUE ENTRIES	TARGET GROUPS	DISTINCT CAS
640	178	639

Production stages as supplied

Commercial	Lab scale	Pilot	R&D
581	27	22	10

Product identity and documentation

The target API describes the intended synthesis project. Four entries are identified as API references because their CAS numbers also appear in the API portfolio. One CAS number and one CAS/salt-form description require clarification before quotation.

Complete downloadable catalogue

The full 640-entry list is supplied as a separate PDF to keep this company profile compact.

www.wwpspharma.com/en/intermediates/

WORKING WITH WWPS

From enquiry to a qualified opportunity

A clear, responsive process helps customers and manufacturing partners move efficiently from an initial requirement to a structured commercial discussion.

01 Share the requirement

API, grade, intended market, dosage form, annual volume, timing and required documentation.

02 Product & partner assessment

WWPS reviews portfolio fit and coordinates an initial assessment with the relevant manufacturing partner.

03 Documentation & commercial alignment

Available technical/regulatory documentation and commercial parameters are confirmed for the project.

04 Qualification & supply coordination

Customer qualification, samples, documentation follow-up and commercial supply are coordinated as applicable.

START A CONVERSATION

WWPS - Worldwide Pharma Solutions

Email	a.kebriaee@wwpspharma.com
Phone / WhatsApp	+351 910 977 994
Website	www.wwpspharma.com
Office	Rua da Alfândega 78 - 3.º andar, 9000-059 Funchal, Portugal
Legal name	WWPS - WORLDWIDE PHARMA SOLUTIONS, UNIPessoal LDA